Jazz Pharma revenues rise 9% in third quarter
Jazz Pharmaceuticals (Nasdaq: JAZZ) has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios.
Net income reached $215 million, or $3.42 per share, marking a significant rise from $147 million in the same quarter last year. Non-GAAP adjusted earnings rose to $6.61 per share.
The company affirmed its full-year revenue guidance of $4 to $4.1 billion, with the neuroscience segment - led by products such as Xywav (calcium, magnesium, potassium, and sodium oxybates) and Epidiolex (cannabidiol) - expected to contribute $2.8-$2.9 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze